Trial Information
Effects of Magnesium Sulphate on the Pharmacodynamics of Rocuronium in Patients 60 Years or Older: Randomised and Double-Blind Study
Inclusion Criteria:
- 60 years or older
- ASA physical status I-III
- Scheduled for elective oncologic head and neck surgery
Exclusion Criteria:
- Severe renal insufficiency (calculated creatinine clearance < 30 ml/min)
- Pre-operatory serum magnesium values > 2.5 mEq/l
- Patients receiving medications known to affect neuromuscular function (furosemide,
aminoglycoside, anticonvulsivants, calcio channel blocker, litium, azatioprine,
cyclofosfamide)
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care
Outcome Measure:
Total recovery time of neuromuscular block (DurTOF0.9)
Outcome Description:
Time from the start of injection of rocuronium until TOF ratio 0.9
Outcome Time Frame:
Within the surgical procedure
Safety Issue:
No
Principal Investigator
Pedro Rotava, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Instituto Nacional de Cancer
Authority:
Brazil: Ministry of Health
Study ID:
MgRoc 60
NCT ID:
NCT01804205
Start Date:
September 2008
Completion Date:
March 2012
Related Keywords:
- Head and Neck Cancer
- magnesium sulfate
- rocuronium
- neuromuscular block
- onset time
- elderly
- Head and Neck Neoplasms